History of cancer and induced menopause: Help – cannot be reconciled

Approximately one in five men or women develops some form of malignant neoplasm (MN) in their lifetimes. Around one in nine men and one in 12 women die from cancer. Ten major types of cancer comprise two-thirds of all new cases of cancer. Now, we can witness a change from impersonal treatment efficacy assessment to a personalized approach, including an analysis of cancer patient’s QoL, his/her age, comorbidity, stage, and immunohistochemical and molecular genetic characteristics of the tumour process. Despite revolutionary advancements in understanding of the molecular biology of tumours, innovative techniques in the development of cytoreductive and anti-tumour treatments, cancer remains one of the most serious health challenges and a leading cause of death worldwide. Challenges in early diagnosis of cancer, the absence of clear markers for tissue "readiness" for tumour growth, the inadequacy of the principle of anti-tumour therapy personalization and a number of other issues do not allow to get out of the vicious circle. The epidemiology of oncological conditions is characterized by gender differences. Breast, lung, and colorectal cancers are the most commonly reported cancer in women. Modern advances in oncology have led to an increase in survival rates in cancer female patients. However, anti-tumour therapy (AT) is characterized by a diverse array of toxic effects on organs and systems. In women, AT is often complicated by premature ovarian failure (POF). Therefore, a significant percentage of women need to u se menopausal hormone therapy (MHT) after successful completion of cancer treatment. This article presents the results of the search for information about the acceptability of MHT for female patients after treatment of non-gynecological cancers, as well as alternative therapy options for menopausal disorders.